financetom
Business
financetom
/
Business
/
Homebuilder Hovnanian Enterprises Q3 revenue rises 10.8% on strong home sales growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Homebuilder Hovnanian Enterprises Q3 revenue rises 10.8% on strong home sales growth
Aug 21, 2025 6:58 AM

Overview

* Hovnanian ( HOV ) Q3 fiscal revenue rises 10.8% to $800.6 mln, meeting estimates

* Net income for fiscal Q3 falls to $16.6 mln from $72.9 mln a year ago

* 86% of total lots are optioned, highest percentage ever achieved

Outlook

* Company expects Q4 revenue between $750 mln and $850 mln

* Hovnanian ( HOV ) sees Q4 adjusted homebuilding gross margin at 15%-16.5%

* Company anticipates Q4 adjusted EBITDA between $77 mln and $87 mln

* Hovnanian ( HOV ) projects Q4 adjusted income before taxes of $45 mln-$55 mln

Result Drivers

* REVENUE INCREASE - Total revenues rose 10.8% to $800.6 mln in Q3, driven by a 9.3% increase in domestic unconsolidated joint ventures' home sales revenues to $165.0 mln

* GROSS MARGIN DECLINE - Homebuilding gross margin percentage, after cost of sales interest expense and land charges, decreased to 11.7% from 19.1% a year ago, with a noted increase in land charges from 0.1% to 2.1%

* CONTRACTS GROWTH - Consolidated contracts in Q3 increased 1.6% to 1,211 homes, while contracts including domestic unconsolidated joint ventures rose 1.4% to 1,416 homes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $800.58 $801.20

Revenue mln mln (1

Analyst)

Q3 EPS $2.14

Q3 Net $16.62

Income mln

Q3 $23.80

Pretax mln

Profit

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the homebuilding peer group is "hold"

* Wall Street's median 12-month price target for Hovnanian Enterprises Inc ( HOV ) is $120.00, about 24.1% below its August 20 closing price of $148.95

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ford to offer free chargers to EV buyers through year-end
Ford to offer free chargers to EV buyers through year-end
Oct 2, 2024
DETROIT, Sept 30 (Reuters) - Ford is trying to woo the electric vehicle-curious by offering free home chargers and installation to buyers of EVs through the end of the year, the company said on Monday. As automakers try to energize sagging EV demand, they've focused on improving access to chargers, along with addressing concerns around price and battery range. There's...
BRIEF-Chain Bridge Bancorp's Current Estimated IPO Price Of Class A Common Stock Will Be $24-$26/Share
BRIEF-Chain Bridge Bancorp's Current Estimated IPO Price Of Class A Common Stock Will Be $24-$26/Share
Oct 2, 2024
Sept 30 (Reuters) - Chain Bridge I ( CBRG ): * CHAIN BRIDGE BANCORP INC SAYS CURRENTLY ESTIMATED IPO PRICE OF CLASS A COMMON STOCK WILL BE BETWEEN $24 AND $26 PER SHARE - SEC FILING * CHAIN BRIDGE BANCORP INC SEES IPO OF UP TO 1.85 MILLION CLASS A SHARES OF COMMON STOCK Further company coverage: ...
Sector Update: Consumer
Sector Update: Consumer
Oct 2, 2024
08:44 AM EDT, 09/30/2024 (MT Newswires) -- Consumer stocks were mixed pre-bell Monday with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) 0.2% lower recently. Yunji ( YJ ) shares were up 14% after the company regained compliance with Nasdaq's minimum bid price requirement for continued listing. ...
Kezar Life Sciences halts mid-stage trial for lupus treatment
Kezar Life Sciences halts mid-stage trial for lupus treatment
Oct 2, 2024
Sept 30 (Reuters) - Kezar Life Sciences ( KZR ) said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an independent committee after four deaths. (Reporting by Sneha S K in Bengaluru) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved